PPARG and Insulin resistance: Pioglitazone is a thiazolidinedione (TZD), targeting the peroxisome proliferator-activated receptor gamma (PPAR-γ), that can reduce insulin resistance and hepatic gluconeogenesis [16,17,18,19,20].